Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1986 Jul;22(1):49–53. doi: 10.1111/j.1365-2125.1986.tb02879.x

The influence of enzyme induction on polymorphic sparteine oxidation.

M Eichelbaum, S Mineshita, E E Ohnhaus, C Zekorn
PMCID: PMC1401070  PMID: 3741726

Abstract

The effects of antipyrine (1200 mg day-1), phenobarbitone (100 mg day-1) and rifampicin (600 mg and 1200 mg day-1, respectively) administration for 7 days on sparteine metabolism and 6 beta-hydroxycortisol excretion were studied in panels of extensive (EM) and poor metaboliser (PM) subjects. Drug metabolism was induced in both EM and PM subjects by antipyrine and rifampicin pretreatment as indicated by increased excretion of 6 beta-hydroxycortisol. A 30% increase in metabolic clearance of sparteine was observed in EM subjects following rifampicin administration whereas in PM subjects no effect on the overall elimination of the drug was seen. The data indicate that the regulation of cytochrome P-450 isozyme involved in polymorphic debrisoquine/sparteine metabolism is predominantly under genetic control and that enzyme induction exerts only a marginal effect.

Full text

PDF
49

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Dengler H. J., Eichelbaum M. Polymorphismen und Defekte des Arzneimittelstoffwechesels als Ursache toxischer Reaktionen. Arzneimittelforschung. 1977;27(96):1836–1844. [PubMed] [Google Scholar]
  2. Eichelbaum M., Bertilsson L., Säwe J., Zekorn C. Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities. Clin Pharmacol Ther. 1982 Feb;31(2):184–186. doi: 10.1038/clpt.1982.29. [DOI] [PubMed] [Google Scholar]
  3. Eichelbaum M. Defective oxidation of drugs: pharmacokinetic and therapeutic implications. Clin Pharmacokinet. 1982 Jan-Feb;7(1):1–22. doi: 10.2165/00003088-198207010-00001. [DOI] [PubMed] [Google Scholar]
  4. Eichelbaum M., Spannbrucker N., Dengler H. J. Influence of the defective metabolism of sparteine on its pharmacokinetics. Eur J Clin Pharmacol. 1979 Sep;16(3):189–194. doi: 10.1007/BF00562060. [DOI] [PubMed] [Google Scholar]
  5. Eichelbaum M., Spannbrucker N., Steincke B., Dengler H. J. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol. 1979 Sep;16(3):183–187. doi: 10.1007/BF00562059. [DOI] [PubMed] [Google Scholar]
  6. Mahgoub A., Idle J. R., Dring L. G., Lancaster R., Smith R. L. Polymorphic hydroxylation of Debrisoquine in man. Lancet. 1977 Sep 17;2(8038):584–586. doi: 10.1016/s0140-6736(77)91430-1. [DOI] [PubMed] [Google Scholar]
  7. Miguet J. P., Mavier P., Soussy C. J., Dhumeaux D. Induction of hepatic microsomal enzymes after brief administration of rifampicin in man. Gastroenterology. 1977 May;72(5 Pt 1):924–926. [PubMed] [Google Scholar]
  8. Ohnhaus E. E., Gerber-Taras E., Park B. K. Enzyme-inducing drug combinations and their effects on liver microsomal enzyme activity in man. Eur J Clin Pharmacol. 1983;24(2):247–250. doi: 10.1007/BF00613826. [DOI] [PubMed] [Google Scholar]
  9. Ohnhaus E. E., Martin J., Kinser J., Colombo J. P. Enzyme induction and renal function in man. Br J Clin Pharmacol. 1977 Feb;4(1):33–37. doi: 10.1111/j.1365-2125.1977.tb00663.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Ohnhaus E. E., Park B. K., Colombo J. P., Heizmann P. The effect of enzyme induction on diazepam metabolism in man. Br J Clin Pharmacol. 1979 Dec;8(6):557–563. doi: 10.1111/j.1365-2125.1979.tb01044.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Ohnhaus E. E., Park B. K. Measurement of urinary 6-beta-hydroxycortisol excretion as an in vivo parameter in the clinical assessment of the microsomal enzyme-inducing capacity of antipyrine, phenobarbitone and rifampicin. Eur J Clin Pharmacol. 1979 Mar 26;15(2):139–145. doi: 10.1007/BF00609878. [DOI] [PubMed] [Google Scholar]
  12. Park B. K. A direct radioimmunoassay for 6 beta-hydroxycortisol in human urine. J Steroid Biochem. 1978 Oct;9(10):963–966. doi: 10.1016/0022-4731(78)90058-4. [DOI] [PubMed] [Google Scholar]
  13. Park B. K. Assessment of urinary 6 beta-hydroxycortisol as an in vivo index of mixed-function oxygenase activity. Br J Clin Pharmacol. 1981 Aug;12(2):97–102. doi: 10.1111/j.1365-2125.1981.tb01186.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Park B. K., Eichelbaum M., Ohnhaus E. E. 6 beta-hydroxycortisol excretion in relation to polymorphic N-oxidation of sparteine. Br J Clin Pharmacol. 1982 May;13(5):737–740. doi: 10.1111/j.1365-2125.1982.tb01448.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Vesell E. S. Genetic and environmental factors affecting drug disposition in man. Clin Pharmacol Ther. 1977 Nov;22(5 Pt 2):659–679. doi: 10.1002/cpt1977225part2659. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES